Vaxart, Inc. (VXRT)
|Net Income (ttm)||-104.60M|
|Day's Range||1.15 - 1.3|
|52-Week Range||1.11 - 7.61|
|Price Target||7.91 (+508.5%)|
|Earnings Date||Nov 8, 2022|
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, wh... [Read more]
In 2021, Vaxart's revenue was $892,000, a decrease of -77.95% compared to the previous year's $4.05 million. Losses were -$70.47 million, 118.7% more than in 2020.Financial Statements
According to 10 analysts, the average rating for VXRT stock is "Buy." The 12-month stock price forecast is 7.91, which is an increase of 508.46% from the latest price.
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine &...
VAXART, INC. (VXRT) delivered earnings and revenue surprises of 4.17% and 100%, respectively, for the quarter ended September 2022.
Growing body of clinical evidence supports transformational potential of Vaxart's oral vaccine platform
VAXART, INC. (VXRT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Select analysts believe these industry game changers can skyrocket over the next year.
Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8
Conference call to begin at 4:30 p.m. ET
SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James Cummings, Chief Medic...
Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan ...
— Study met primary safety and secondary immunogenicity endpoints —
Vaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 Trial
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced it will release top-line data from the first part of its planned two-part COVID-19 Phase II tri...
Dr. Stapleton has more than 20 years of industry experience leading technical, quality and manufacturing operations at commercial and clinical stage biopharmaceutical companies
Dr. Heron brings decades of experience in executive leadership and life sciences research and development to Vaxart's Board Dr. Heron brings decades of experience in executive leadership and life scienc...
VAXART, INC. (VXRT) delivered earnings and revenue surprises of -9.52% and 100%, respectively, for the quarter ended June 2022.
Top-line data from COVID-19 Phase II study expected in the third quarter of 2022
Non-executive director to bring extensive life science industry and finance experience
All six proposals approved in the 2022 Proxy Statement
Vaxart is still in the coronavirus vaccine race, even though its competitors remain very far ahead.
Vaxart to Host Second Quarter 2022 Business Update and Financial Results Conference Call on August 8
Conference call to begin at 4:30 p.m. ET Conference call to begin at 4:30 p.m. ET
Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by Augu...
Key Proposal #2 Needs an Additional 0.9% of Outstanding Shares Votes to Pass
Vaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immun...
Vaccine-induced mucosal IgA antibody responses persisted for up to 1 year and had a higher neutralizing activity compared with convalescent samples
Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022
SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. Rebecca Flitter, Senior Scient...
Vaxart Provides an Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022 to Vote by July 5...
Key Proposal #2 has received significant support, but additional votes are needed for approval
Model will be used in Vaxart's Phase II Omicron Challenge Trial
Management to discuss progress on its programs, annual stockholders' meeting proposals
It depends on which subsector you're talking about.